TY - JOUR
T1 - Genetic ablation of delta opioid receptors in nociceptive sensory neurons increases chronic pain and abolishes opioid analgesia
AU - Gaveriaux-Ruff, Claire
AU - Nozaki, Chihiro
AU - Nadal, Xavier
AU - Hever, Xavier C.
AU - Weibel, Raphael
AU - Matifas, Audrey
AU - Reiss, David
AU - Filliol, Dominique
AU - Nassar, Mohammed A.
AU - Wood, John N.
AU - Maldonado, Rafael
AU - Kieffer, Brigitte L.
N1 - Funding Information:
We thank Gregory Scherrer, Columbia University Medical Center, Department of Physiology and Cellular Biophysics, New York, for the construction and first characterization of Oprd1 floxed animals at IGBMC. We thank E. Metzger, A. Van Es and the IGBMC animal facility, G. Duval, D. Memedov, L. Masson, and Y. Grassini for technical assistance and animal care. We thank the Mouse Clinic Institute for their contribution in mouse engineering and animal care. This work was supported by Université de Strasbourg (UdS, CGR), CNRS, INSERM, Région Alsace (X.C.H.), Fondation pour la Recherche Médicale (C.N., G.S.), Ministerio de Educacion y Ciencia (SAF2007-64062, R.M.), the US National Institutes of Health (NIAAA 016658, B.L.K.; NIDA 005010, B.L.K.; NIDA 016768, B.L.K. and R.M.), and the European Union (GENADDICT/FP6 005166, B.L.K. and R.M.); and the Wellcome Trust, MRC, and BBSRC (J.N.W.).
PY - 2011/6
Y1 - 2011/6
N2 - Opioid receptors are major actors in pain control and are broadly distributed throughout the nervous system. A major challenge in pain research is the identification of key opioid receptor populations within nociceptive pathways, which control physiological and pathological pain. In particular, the respective contribution of peripheral vs. central receptors remains unclear, and it has not been addressed by genetic approaches. To investigate the contribution of peripheral delta opioid receptors in pain control, we created conditional knockout mice where delta receptors are deleted specifically in peripheral NaV1.8-positive primary nociceptive neurons. Mutant mice showed normal pain responses to acute heat and to mechanical and formalin stimuli. In contrast, mutant animals showed a remarkable increase of mechanical allodynia under both inflammatory pain induced by complete Freund adjuvant and neuropathic pain induced by partial sciatic nerve ligation. In these 2 models, heat hyperalgesia was virtually unchanged. SNC80, a delta agonist administered either systemically (complete Freund adjuvant and sciatic nerve ligation) or into a paw (sciatic nerve ligation), reduced thermal hyperalgesia and mechanical allodynia in control mice. However, these analgesic effects were absent in conditional mutant mice. In conclusion, this study reveals the existence of delta opioid receptor-mediated mechanisms, which operate at the level of Na V1.8-positive nociceptive neurons. Delta receptors in these neurons tonically inhibit mechanical hypersensitivity in both inflammatory and neuropathic pain, and they are essential to mediate delta opioid analgesia under conditions of persistent pain. This delta receptor population represents a feasible therapeutic target to alleviate chronic pain while avoiding adverse central effects. The conditional knockout of delta-opioid receptor in primary afferent NaV1.8 neurons augmented mechanical allodynia in persistent pain models and abolished delta opioid analgesia in these models.
AB - Opioid receptors are major actors in pain control and are broadly distributed throughout the nervous system. A major challenge in pain research is the identification of key opioid receptor populations within nociceptive pathways, which control physiological and pathological pain. In particular, the respective contribution of peripheral vs. central receptors remains unclear, and it has not been addressed by genetic approaches. To investigate the contribution of peripheral delta opioid receptors in pain control, we created conditional knockout mice where delta receptors are deleted specifically in peripheral NaV1.8-positive primary nociceptive neurons. Mutant mice showed normal pain responses to acute heat and to mechanical and formalin stimuli. In contrast, mutant animals showed a remarkable increase of mechanical allodynia under both inflammatory pain induced by complete Freund adjuvant and neuropathic pain induced by partial sciatic nerve ligation. In these 2 models, heat hyperalgesia was virtually unchanged. SNC80, a delta agonist administered either systemically (complete Freund adjuvant and sciatic nerve ligation) or into a paw (sciatic nerve ligation), reduced thermal hyperalgesia and mechanical allodynia in control mice. However, these analgesic effects were absent in conditional mutant mice. In conclusion, this study reveals the existence of delta opioid receptor-mediated mechanisms, which operate at the level of Na V1.8-positive nociceptive neurons. Delta receptors in these neurons tonically inhibit mechanical hypersensitivity in both inflammatory and neuropathic pain, and they are essential to mediate delta opioid analgesia under conditions of persistent pain. This delta receptor population represents a feasible therapeutic target to alleviate chronic pain while avoiding adverse central effects. The conditional knockout of delta-opioid receptor in primary afferent NaV1.8 neurons augmented mechanical allodynia in persistent pain models and abolished delta opioid analgesia in these models.
KW - Conditional gene knockout
KW - Delta
KW - Inflammation
KW - Neuropathy
KW - Nociceptive pathway
KW - Opioid receptor
UR - http://www.scopus.com/inward/record.url?scp=79956153093&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79956153093&partnerID=8YFLogxK
U2 - 10.1016/j.pain.2010.12.031
DO - 10.1016/j.pain.2010.12.031
M3 - Article
C2 - 21295407
AN - SCOPUS:79956153093
SN - 0304-3959
VL - 152
SP - 1238
EP - 1248
JO - Pain
JF - Pain
IS - 6
ER -